High-Intensity Interval Training (HIIT) Exercise to Improve Docetaxel Chemotherapy Tolerability in Metastatic Prostate Cancer
Lay Description
We are investigating the use of high-intensity interval training (HIIT) to improve participant’s ability to tolerate docetaxel chemotherapy treatments for metastatic prostate cancer.
Category
- Cancers and Other Neoplasms
- Mens Health
- Prostate Cancer
- IRB Number
- 20210663HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Min 18 - No Max
- Eligible Genders
- Male
- Accepts Healthy Volunteers
Inclusion Criteria
- Diagnosis of metastatic prostate cancer
- Planning to receive docetaxel chemotherapy treatment
- Have not started chemotherapy treatment.
- Willing to commit to 3 in-person study visits per week over the course of the study
- At least 4 weeks after from any major surgery
Exclusion Criteria
- Uncontrolled high blood pressure (hypertension)
- Diagnosis of small cell neuroendocrine prostate cancer
- Receiving any other chemotherapy drug besides docetaxel
- Heart attack, stroke, or transient ischemic attack in the last 6 months
- Heart failure
- Chest pain (angina)
- Secondary cancer (may be eligible if second cancer is non-melanoma skin cancer or non-invasive bladder cancer)
- Severe bone pain
- Physical limitations that would prevent exercise participation
- Already active (more than 1 hour per day of vigorous aerobic exercise or structured resistance exercise for 2 or more days per week)
- Uncontrolled asthma
Study Design
Arm Groups
Study Contact
Regulatory Point of Contact
Crisann Moon
(210) 288-0488
moonc1@uthscsa.edu
Regulatory Point of Contact
Darpan Patel
(210) 567-0362
pateld7@uthscsa.edu
Local Recruitment Point of Contact
Crisann Moon
(210) 288-0488
moonc1@uthscsa.edu
Principal Investigator
Darpan Patel